Catalio Capital Management »

Metagenomi shares owned by Catalio Capital Management

Quarter-by-quarter ownership of Metagenomi (MGX) shares owned by Catalio Capital Management from 13F filings

Historical chart of Catalio Capital Management investment in Metagenomi

Tip: Access up to 7 years of quarterly data

All positions including Metagenomi held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Metagenomi by Catalio Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.3M 529k 2.37

More positions owned by Catalio Capital Management

Eli Lilly & Co. (LLY)
Abbvie (ABBV)
Bridgebio Pharma (BBIO)
Intuitive Surgical Com New (ISRG)
Ascendis Pharma A/s Sponsored Adr (ASND)
Soleno Therapeutics (SLNO)
Dianthus Therapeutics (DNTH)
Boston Scientific Corporation (BSX)
Syndax Pharmaceuticals (SNDX)
Cytokinetics Com New (CYTK)
Natera (NTRA)
Regeneron Pharmaceuticals (REGN)
Structure Therapeutics Sponsored Ads (GPCR)
Uniqure Nv SHS (QURE)
Disc Medicine (IRON)

View all positions for Catalio Capital Management

Top funds holding Metagenomi

Vanguard Group
Sozo Ventures GP II
Catalio Capital Management
Peapod Lane Capital
Millennium Management
Geode Capital Management
Pura Vida Investments
Morgan Stanley
BlackRock
Two Sigma Investments
Good Life Advisors
Bridgeway Capital Management
Renaissance Technologies
State Street Corporation
Wells Fargo & Company

View all funds holding Metagenomi